Fig. 8
MGD-28 has profound cytotoxic activity in different stage of MM cells and shows a broad antiproliferative profile. A-E. The expression level of IKZF1 (A), IKZF2 (B), IKZF3 (C), CK1α (D) and CRBN (E) in MM specimens at different stages. * p < 0.05, ** p < 0.01. F-G. Viability assay of four MM PDCs (1, 3, 5, or 7) treated with MGD-28 (F) or pomalidomide (G) for 4 days. Data shown are a representative graph of three independent experiments; mean ± SD of triplicates. H. Viability assay of primary B cells obtained from the 3 MM patients (MM-P1. MM-P2 and MM-P3) treated with MGD-28 for 4 days. Data shown are a representative graph of three independent experiments; mean ± SD of triplicates. I. Flow cytometry plot showing PDC-7 treated with indicated compounds for 3 days, stained with Annexin V-PE and DAPI. Histograms show the relative cell percentage of apoptosis in PDC-7. Error bars denote standard deviations (independent experiments, n = 3). Student’s t test, ns (no significance), **p < 0.01. J. Western blot analysis of PDC-7 treated with different concentrations of MGD-28 for 24 h. K. IC50 values of MGD-28 for the 46 solid cancer cell lines and 6 normal cell lines relative to the panel average IC50